PRLDNasdaqPharmaceutical PreparationsUS GAAP · USD

Prelude Therapeutics Inc

Prelude Therapeutics Inc. is a U.S.-based precision oncology biotechnology company focused on discovering and developing novel cancer medicines. The company builds small-molecule drug candidates and other proprietary programs from its research platform and advances selected assets into preclinical and clinical development, often in collaboration with partners.

Ask about the company
Revenue12.1m USD
+73.4 %y/y
Operating profit (EBIT)-105m USD
+25.2 %y/y
EBIT margin-861.3%
+1,134.6 ppy/y
Net income-99.5m USD
+21.8 %y/y
Free cash flow-56.4m USD
+45.6 %y/y

Fiscal year 2025 · change from previous year

Development 2020–2025

-150-100-50050m USD2020: EBIT -59 m USD20202021: EBIT -114 m USD20212022: EBIT -124 m USD20222023: EBIT -132 m USD20232024: 7.0 m USD2024: EBIT -140 m USD20242025: 12 m USD2025: EBIT -105 m USD202512-105
RevenueOperating profit (EBIT)

Business

Share of revenue
Precision oncology drug candidates70 %

Novel cancer medicines designed to target specific biological drivers in tumors.

Collaborative research and license revenue20 %

Revenue from collaboration amendments, licenses, and related know-how transfers.

Preclinical discovery programs10 %

Early-stage proprietary programs and target discovery efforts not yet in trials.

Customers

Prelude’s direct customers are primarily pharmaceutical and biotechnology partners that enter collaboration, license, or research arrangements with the company. Its eventual end users are cancer patients and the physicians who prescribe approved therapies, but the current business model is centered on partnering and advancing drug candidates rather than commercial product sales. Third-party payors and healthcare systems become relevant only if a candidate reaches commercialization.

Biopharmaceutical collaboration partners

Partners such as AbCellera and other drug developers that fund or co-develop oncology programs, licenses, or discovery assets.

Future oncology prescribers and patients

Oncologists and cancer patients who would use approved therapies if candidates successfully reach the market.

Clinical research ecosystem

CROs, investigative sites, and trial networks that support preclinical and clinical development.

Strategy

Prelude’s strategy is to use its cancer biology and medicinal chemistry platform to identify high-value oncology targets and create differentiated new chemical entities. It advances selected programs into clinical trials, seeks external collaborations to extend its pipeline, and uses partnerships to support discovery and funding needs. The company also emphasizes building assets with strong selectivity and oral bioavailability, which can improve differentiation in crowded oncology categories.

Advance lead precision oncology candidatesShort term

Clinical progress is the main path to value creation in a pre-commercial biotech model.

Build and diversify collaboration revenueShort term

Partnerships can provide non-dilutive capital and external validation of the platform.

Expand the discovery platformMedium term

A broader pipeline increases the chance of finding assets that can reach the clinic or attract partners.

Geography

Prelude is headquartered in Wilmington, Delaware and operates as a U.S.-based biotechnology company. Its research, development, and clinical activities are centered in the United States, while competition, scientific collaboration, and future commercialization opportunities are global in scope. The company’s exposure is therefore concentrated in U.S. regulatory, reimbursement, and capital-market conditions, with broader international competition in oncology drug development.

Risks

Prelude faces the typical risks of an early-stage oncology biotech: clinical failure, regulatory setbacks, and intense competition from better-capitalized drug developers. It also depends on external financing and collaboration income, so delays in development or partner support can materially affect its ability to continue operations. Because it has not yet commercialized a product, future value depends heavily on successful trial outcomes and eventual regulatory approval.

Sorted by severity
LowMediumHighLowMediumHighImpact →Likelihood →Clinical development failure1Financing and going-concern risk2Competitive pressure in precision oncology3Regulatory and reimbursement uncertainty4
Impact is the risk’s severity and likelihood how probable it is over the next few years, both assessed from the company’s reports. Numbers match the list.
  1. Clinical development failureImpact: CriticalLikelihood: High

    Drug candidates may not prove safe or effective in trials, which would halt or delay value creation.

    Exposure: Lead oncology programs and preclinical assets

  2. Financing and going-concern riskImpact: CriticalLikelihood: High

    The company relies on external capital and collaboration proceeds to fund operations before product revenue exists.

    Exposure: Corporate funding and pipeline continuity

  3. Competitive pressure in precision oncologyImpact: HighLikelihood: Medium

    Large pharma and biotech peers may develop similar targets faster or with more resources.

    ExposureJAK2V617FKAT6ASMARCA2Related oncology programs
  4. Regulatory and reimbursement uncertaintyImpact: MediumLikelihood: High

    Even approved oncology drugs face FDA review risk and later payor coverage pressure.

    Exposure: Future commercial products in the U.S.

Accounting

Judgemental items
ASC 606 collaboration and license revenue

Revenue is recognized when performance obligations are satisfied, so timing of amendments and license transfers matters.

Impact: Can create lumpy quarterly revenue from partner agreements

Stock-based compensation valuation

Option expense depends on volatility, expected term, and other assumptions for a public biotech issuer.

Impact: Can materially affect reported R&D and G&A expense

Research and development expense timing

Clinical and preclinical costs are expensed as incurred and vary with program activity.

Impact: Drives quarter-to-quarter operating loss volatility

Lease and sublease accounting

Office lease obligations and sublease income affect occupancy-related expenses and cash flows.

Impact: Can change reported facilities cost and future commitments

Similar listed companies

Publicly listed companies with a comparable business focus.

OnKure Therapeutics, Inc.

OKUR · Pharmaceutical Preparations

Decoy Therapeutics Inc.

DCOY · Pharmaceutical Preparations

Replimune Group, Inc.

REPL · Biological Products, (No Diagnostic Substances)

Propanc Biopharma, Inc.

PPCB · Pharmaceutical Preparations

Precipio, Inc.

PRPO · Laboratory Analytical Instruments

Relay Therapeutics, Inc.

RLAY · Biological Products, (No Diagnostic Substances)

Last updated: 24/09/2026